Lonza consensus on margins and growth, shares in Swiss large-cap focus

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-27, 11:17.

Lonza Group AG (CH0013841017) sits in a phase where analysts focus closely on margin recovery and growth visibility, with the stock trading on SIX Swiss Exchange as part of the Swiss Market Index SMI. Consensus data show a mixed but broadly constructive stance on the life sciences group, with several houses maintaining Buy or Outperform recommendations alongside neutral views.

What recent analyst data show

Consensus compilations for Lonza indicate that a majority of covering analysts rate the stock at Buy or equivalent, while a minority stay at Hold, reflecting cautious optimism on the medium-term earnings path.MarketScreener analyst overview for Lonza Target price averages cluster moderately above the current share price in Swiss francs, with dispersion driven by differing views on biopharma services demand and execution risk in ongoing capacity projects.finanzen.net Lonza analyst summaries

Several international research houses highlight Lonza's exposure to biologics manufacturing and contract development services as a structural positive, but point to the need for clearer margin traction after past investment phases in new facilities and technology platforms.MSN aggregation of Lonza broker recommendations The spread between the highest and lowest published 12-month price targets marks a significant range, underlining differing assumptions on utilization rates and pricing power in key segments.

How Lonza stock trades today

On SIX Swiss Exchange, Lonza shares trade in the large-cap SMI segment and recently changed hands moderately below their 52-week high, with the price reflecting a balance between margin recovery hopes and valuation discipline.SIX share explorer for Lonza Trading volumes on typical days mirror a broad international investor base, including institutions benchmarking against Swiss and European indices.

Some investors compare Lonza with global peers such as Thermo Fisher Scientific or Catalent in the contract development and manufacturing space, watching relative valuation metrics like EV/EBITDA and price-to-earnings alongside growth expectations.Reuters key metrics for Lonza and peers Over recent months, the shares have traded within a corridor that reflects both sector-wide sentiment in life sciences tools and company-specific execution on capacity and portfolio projects.

The business behind the stock

Lonza earns most of its revenue in contract development and manufacturing services for biopharmaceuticals and in specialty ingredients for healthcare and nutrition, operating facilities across Europe, North America and Asia.Lonza company profile A representative offering is its mammalian cell culture biologics manufacturing platforms, where the company provides end-to-end services from process development through commercial-scale production for pharmaceutical customers.

Where the Lonza shares trade

The Lonza shares (CH0013841017) trade on SIX Swiss Exchange in Zurich, where they recently quoted in the high triple-digit Swiss franc range during regular trading hours, with the latest available price data in CHF reflecting their status as a core Swiss large-cap name.

Disclaimer: This text is for informational purposes only and does not constitute investment advice, a recommendation to buy or sell any security, or a solicitation of any kind. Figures and dates are based on sources believed to be reliable at the time of writing but may change. Readers should conduct their own research or consult a professional adviser before making investment decisions.